Tag Archive: oxforduniversity

  1. Professor Tomáš Hanke speaks to Scientia about innovative methods in vaccine design and development to combat HIV.

    Leave a Comment

    Prof Hanke, EAVI2020 PI at the University of Oxford spoke to Scientia which included his work on T cell response to second-generation conserved immunogen, HIVconsvX, and its predecessor, HIVconsv. Scientia is a popularised outreach journal that provides researchers with a platform to communicate their findings to others outside their speciality. Technical nomenclature is often transcribed into easier formats allowing further reach of the scientific outputs for maximising social impact, and engaging stakeholders.

    Read the full article at the Scientia website.

    Professor Tomáš Hanke – Use of Experimental Medicine for Rational Development of an Effective HIV Vaccine

    Aug 12, 2020 | BiologyHealth and Medicine

    Reference
    https://doi.org/10.33548/SCIENTIA538

    screenshot of Scientia article on website

  2. Presentations from EAVI2020 partners at the 2016 Keystone Symposia on HIV Vaccines are available online!

    Leave a Comment

    The Global HIV Vaccine Enterprise in collaboration with Keystone Symposia organized an ePanel discussion and series of SciTalks presentations that brought together key experts in the HIV prevention vaccine field.

    The ePanel and SciTalks addressed a broad range of topics pertinent to state-of-the-art HIV vaccine research. As part of the Global HIV Vaccine Enterprise eAccess Meetings initiative, videos of several presentations recorded onsite at the 2016 Keystone Symposia on HIV Vaccines are available.


    EAVI2020 – present at the 2016 Keystone Symposia on HIV Vaccines

    The Keystone Symposia highlighted cutting-edge scientific developments and challenges in the field in 90-minute sessions that included SciTalk presentations by EAVI2020 Partners:

    Professor Tomas Hanke, from the University of Oxford, presented “A novel conserved-region T-cell mosaic vaccine with very high global coverage of HIV-1 variants is recognized by protective responses in chronic untreated infection” and his presentation is available as a webcast.

    Dr Marit van Gils, from Academisch Medisch Centrum, received the New Investigator Award at HIVR4P and presented “A broadly neutralizing antibody from an elite neutralizer, targets a novel site at the gp120-gp41 interface”. Her presentation is available as a webcast.

    More information

    eAccess Meetings past presentations.
    For more information about EAVI2020, please contact us.